GET DAILY SIGNALSLegend Biotech (LEGN): Central Analyst Target of $48 Implies +140% Upside
Key Takeaways
- The central target of $48 is the arithmetic mean of nine current analyst price targets reviewed for this article, not an official published consensus.
- The stock was trading near $19.96 in the November 10, 2026 session, down roughly 18% after a third-quarter earnings miss, implying a required upside of about 140% to reach $48 — a very large move.
- Analyst targets span an unusually wide range from $24 (UBS) to $68 (Barclays), reflecting sharp disagreement about Legend Biotech's growth trajectory and valuation.
- The strongest supports are continued growth of its CARVYKTI (ciltacabtagene autoleucel) CAR-T therapy, an earlier-line expansion opportunity, and a broader cell-therapy pipeline.
- The biggest risks are profitability pressure, a recent EPS (earnings per share) miss, competition in multiple myeloma, and repeated analyst downgrades and target cuts through 2026.
- For more context on the company's developments and market reaction, explore its Major News, Today's Price Move, Forecast, and Earnings pages.
- Readers looking for AI-driven market analysis can explore Trending AI Robots for automated insights across stocks and ETFs.
Analyst Price Targets and Consensus View
Legend Biotech Corporation (LEGN) is a clinical-stage biopharmaceutical company focused on cell therapies, led by CARVYKTI, a CAR-T (chimeric antigen receptor T-cell) treatment for multiple myeloma developed and commercialized with Janssen, part of Johnson & Johnson. The nine analyst targets reviewed range from a low of $24 to a high of $68, an unusually wide dispersion that itself signals how divided the Street is on the stock.
The most recent targets include Barclays at $68, H.C. Wainwright at $65, Piper Sandler at $64, and RBC Capital at $56, alongside more cautious views from Morgan Stanley at $48, Oppenheimer at $40 (which downgraded the stock to Hold in August), Goldman Sachs at $38, J.P. Morgan at $33, and UBS at $24. Averaging these nine figures yields roughly $48.4, rounded to a central target of $48. Bullish analysts emphasize CARVYKTI's commercial momentum and earlier-line potential, while cautious analysts focus on profitability, competitive pressure, and valuation. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Market Position and Path Toward the Target
With the stock near $19.96, reaching $48 would require a gain of approximately 140%, a very large move that would more than double the share price. The company reported third-quarter EPS of -$0.13, missing the roughly breakeven estimate, even as revenue of about $359.5 million slightly topped consensus. Trailing twelve-month revenue is around $1.27 billion, with the company still operating at a net loss. CARVYKTI sales have grown strongly, but the path to a $48 target depends on converting that revenue growth into durable profitability, expanding into earlier lines of multiple myeloma therapy, and advancing pipeline assets such as the DLL3-targeted CAR-T candidate LB2102.
What Could Support a Move Toward the Target
- CARVYKTI revenue growth, which has shown strong year-over-year gains and rising collaboration revenue.
- Earlier-line expansion through trials such as CARTITUDE-5, which could meaningfully widen the addressable patient population.
- Encouraging long-term survival data and real-world evidence presented at hematology meetings.
- Pipeline optionality beyond multiple myeloma, including early solid-tumor data for LB2102.
- A strong cash position (roughly $965 million in the most recent quarter) that funds continued development.
What Could Prevent the Target From Being Reached
- Persistent losses and a recent EPS miss that raise questions about the pace of profitability.
- Competition in multiple myeloma from bispecific antibodies and other CAR-T therapies.
- Repeated analyst downgrades and target reductions through 2026, including Oppenheimer's August downgrade to Hold.
- A public share offering in mid-2026 that diluted existing holders.
- Executive turnover, including a CEO transition announced in 2026, which can create execution uncertainty.
Technical Levels and Market Structure
Over the past 52 weeks, LEGN has traded between $16.24 and $37.50. The $16.24 low represents a key support level, while the $37.50 high marks the most significant resistance zone below the $48 target. The stock's 50-day and 200-day moving averages sat near $19.67 and $22.15 respectively, and the sharp November decline pushed the shares back toward these trend measures. A sustained move toward $48 would first require reclaiming the $22–$24 zone and then clearing the 52-week high, a substantial technical hurdle given current momentum. From what I see, reviewing the technical setup with AI tools helps clarify these levels.
Time Horizon and What Investors Should Monitor
Analyst price targets typically reflect a research horizon of roughly 12 months, though firms do not always state a uniform timeframe and targets set before the latest earnings release may be revised. Investors should monitor quarterly CARVYKTI sales, guidance on profitability, updates from the CARTITUDE clinical program, any changes to analyst targets or ratings, and broader biotechnology-sector sentiment, which has influenced valuation across cell-therapy names.
AI Daily Buy/Sell Signals
In my analysis, Tickeron's AI Daily Buy/Sell Signals have been useful for tracking names like this one. They apply artificial intelligence to monitor thousands of stocks and ETFs in real time, producing Buy, Sell, or Hold signals based on market conditions, technical factors, and AI analysis. For a volatile stock such as LEGN, these signals offer a way to identify potential opportunities, track positions, and notice trend shifts without relying solely on manual checks. I find them a practical addition to the broader research process when evaluating situations with wide analyst dispersion.
Final Assessment
The central target of $48 is the average of nine current analyst price targets spanning $24 to $68, and it sits far above the stock's recent trading level near $19.96, implying a roughly 140% move. Support for such a move rests on CARVYKTI's continued growth, earlier-line expansion, and pipeline progress, while the principal obstacles are ongoing losses, the latest EPS miss, competitive pressure, and the wave of target cuts and downgrades seen over the past year. The wide analyst range underscores that this is a high-uncertainty, high-dispersion situation rather than a clear consensus. Investors should focus on upcoming earnings, CARVYKTI sales trends, and any analyst revisions rather than treating the $48 figure as a predictable outcome.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
LEGN in upward trend: 10-day moving average crossed above 50-day moving average on October 28, 2026
The 10-day moving average for LEGN crossed bullishly above the 50-day moving average on October 28, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 11 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
LEGN moved above its 50-day moving average on October 26, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +7.76% 3-day Advance, the price is estimated to grow further. Considering data from situations where LEGN advanced for three days, in 176 of 253 cases, the price rose further within the following month. The odds of a continued upward trend are 70%.
The Aroon Indicator entered an Uptrend today. In 106 of 133 cases where LEGN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 80%.
Bearish Trend Analysis
The 10-day RSI Indicator for LEGN moved out of overbought territory on November 10, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 23 similar instances where the indicator moved out of overbought territory. In 20 of the 23 cases, the stock moved lower in the following days. This puts the odds of a move lower at 87%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 51 of 57 cases where LEGN's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 89%.
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on LEGN as a result. In 91 of 100 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LEGN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
LEGN broke above its upper Bollinger Band on October 26, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 4 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.701) is normal, around the industry mean (3.498). P/E Ratio (-46.800) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (2.478) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 43 (best 1 - 100 worst), indicating steady price growth. LEGN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 45 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 93 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LEGN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a holding company which engages in the discovery and development of novel cell therapies for oncology and other indications
Industry Biotechnology
Advertisement